Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 85

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 85
---
 Bill Act (the “OBBBA”) was enacted, resulting in changes to U.S. federal income tax law. Significant provisions of the OBBBA include the permanent extension of certain provisions of the 2017 Tax Cuts and Jobs Act, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. In accordance with ASC 740, Income Taxes, the Company is required to recognize the effect of the tax law changes in the period of enactment, such as remeasuring its estimated U.S. deferred tax assets and liabilities. The Company has $124.6 million of a gross deferred tax asset attributed to unamortized U.S. capitalized research and development costs as of December 31, 2024 that will be deductible on its 2025 and 2026 income tax returns. There are no other material impacts to the Company related to the enactment of the OBBBA.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  29

NOTE 15—CONTINGENT CONSIDERATION CHARGES (GAINS), ACQUISITION-RELATED EXPENSES, RESTRUCTURING AND OTHER

Contingent consideration charges (gains), acquisition-related expenses, restructuring and other for the nine months ended September 30, 2025 and 2024 summarized below (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Contingent consideration charges (gains)$625 $(3,244)$(2,407)$(5,541)Restructuring charges3,728 1,193 3,728 7,724 Acquisition-related expenses(280)285 2,222 689 Legal settlement— — 7,000 — Legal judgment(23,148)— (23,148)— Impairment of acquired IPR&D25,866 — 25,866 — Total contingent consideration charges (gains), acquisition-related expenses, restructuring and other$6,791 $(1,766)$13,261 $2,872 Flexion Acquisition Contingent ConsiderationThe Company recognized charges of $0.6 million and gains of $2.4 million related to contingent consideration arising from the Flexion Acquisition during the three and nine months ended September 30, 2025, respectively. The Company recognized gains of $3.2